Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01051921 · ClinicalTrials.gov registry record · Phase 2
Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders
A Phase 2 study of Hepatitis C, sponsored by Conatus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 15
- Study locations
NCT01051921: Completed Phase 2 study of Hepatitis C, sponsored by Conatus Pharmaceuticals.
NCT01051921 is a Phase 2 study of Hepatitis C that has completed, run by Conatus Pharmaceuticals. The registered enrollment target is 67 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (96% lower). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01051921, a Phase 2 study of Hepatitis C, has completed, sponsored by Conatus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to determine if the combination treatment of CTS-1027, pegylated interferon and ribavirin can improve the response rates in HCV patients who did not previously respond to pegylated interferon and ribavirin therapy.
Primary Outcome
Early Virologic Response (EVR) is defined as the percent of patients who experienced a drop in HCV-RNA (Hepatitis C Ribonucleic acid, also known as "viral load") levels of more that 2 log from before treatment (baseline) through 12 Weeks of treatment.
Conditions Studied
Interventions
- DRUG Ribavirin
- DRUG CTS-1027
- DRUG Pegylated interferon
Study Locations (15)
California
- Scripps Clinic - La Jolla
- VA Medical Center, San Diego - San Diego
Colorado
- University of Colorado Health Science Center - Denver
- South Denver Gastroenterology - Englewood
Texas
- Advanced Liver Therapies - Baylor College of Medicine - Houston
- VA Medical Center, Houston - Houston
Georgia
- Digestive Healthcare of Georgia - Atlanta
Louisiana
- Tulane University Health Sciences Center - New Orleans
Michigan
- Henry Ford Medical Center-Columbus - Novi
Minnesota
- MN Clinical Research Center - Plymouth
Missouri
- St. Louis University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT01051921 record still lists
NCT01051921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 3 interventions - of which Ribavirin is the first listed.
NCT01051921 lists 15 locations in 12 states (California, Colorado, Texas).
Frequently Asked Questions
What is clinical trial NCT01051921 about?
NCT01051921 is a clinical study titled "Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders". The purpose of this study is to determine if the combination treatment of CTS-1027, pegylated interferon and ribavirin can improve the response rates in HCV patients who did not previously respond to pegylated interferon and ribavirin therapy.
What is the current status of trial NCT01051921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2010-01. Estimated completion is 2011-12.
What conditions does trial NCT01051921 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT01051921?
The interventions under investigation include: Ribavirin (DRUG), CTS-1027 (DRUG), Pegylated interferon (DRUG).
Who is sponsoring clinical trial NCT01051921?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01051921 being conducted?
This trial has 15 study locations across California, Colorado, Georgia, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01051921's enrollment target sits among peer trials
67 66th of 106 higher than 41 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
COMPLETED · Phase 2
-
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
COMPLETED · Phase 2
-
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia